Actinium Pharmaceuticals ... (ATNM)
AMEX: ATNM
· Real-Time Price · USD
1.50
-0.02 (-1.32%)
At close: May 01, 2025, 3:59 PM
1.60
6.67%
Pre-market: May 02, 2025, 04:39 AM EDT
-1.32% (1D)
| Bid | 1.52 |
| Market Cap | 46.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.24M |
| EPS (ttm) | -1.27 |
| PE Ratio (ttm) | -1.18 |
| Forward PE | -1.5 |
| Analyst | Buy |
| Ask | 1.8 |
| Volume | 296,073 |
| Avg. Volume (20D) | 639,980 |
| Open | 1.51 |
| Previous Close | 1.52 |
| Day's Range | 1.44 - 1.54 |
| 52-Week Range | 1.03 - 10.24 |
| Beta | -0.27 |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 27, 2012
Employees 37
Stock Exchange AMEX
Ticker Symbol ATNM
Website https://www.actiniumpharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 233.33% from the latest price.
Stock Forecasts1 month ago
+18.35%
Actinium Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
1 month ago
+16.53%
Actinium Pharmaceuticals shares are trading higher after the company announced it entered a research collaboration with Memorial Sloan Kettering for clinical expansion of Actimab-A's backbone therapy strategy.
